Chief Financial Officer · iTeos Therapeutics, Inc. (ITOS)

Matthew Gall

FY2023 is the first fiscal year CompBrief holds for Matthew Gall as a named executive officer of iTeos Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$2,715,441

Salary $441,150Stock awards $403,440

3rd of 3 named executive officers at iTeos Therapeutics by FY2023 total.

3 named officers on file for iTeos Therapeutics, FY2023

Matthew Gall’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how iTeos Therapeutics’s whole pay program stands against its peers

  • iTeos Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ITOS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 25, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Matthew Gall’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Matthew Gall compensation by year

iTeos Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as iTeos Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$441,150
Bonus$0
Stock awards$403,440
Option awards$1,664,000
Non-equity incentive$191,851
Pension and deferred compensation$0
All other$15,000
Total$2,715,441

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: iTeos Therapeutics, Inc. DEF 14A filed April 25, 2024, accession 0000950170-24-047915, and prior-year filings.

How this page was built: the iTeos Therapeutics, Inc. filed document, accession 0000950170-24-047915. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2024.

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU41,000$448,950—
Option39,635—$6.16
Option47,812—$36.21
Option22,500—$41.58
Option9,000—$23.19
Option130,000—$16.66

Per the Outstanding Equity Awards at Fiscal Year-End table in iTeos Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

9 Form 4 lines since the FY2023 proxy (filed April 25, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2025-08-29U—89,429—0
2025-08-29Disposition to the issuer derivative—8,123—0
2025-08-29Disposition to the issuer derivative—135,937—0
2025-08-29Disposition to the issuer derivative—42,388—0
2025-08-29Disposition to the issuer derivative—252,135—0
2025-08-29Disposition to the issuer derivative—9,063—0
2025-03-07Grant or award—24,000$0.0089,429
2025-03-07Grant or award derivative—145,000$0.00145,000

The 8 most recent of 9 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

iTeos Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Michel DetheuxChief Executive Officer$5,767,774
Matthew CallChief Operating Officer$2,803,174
Matthew Gall · this pageChief Financial Officer$2,715,441

The full iTeos Therapeutics compensation record

free company brief

This page is one person within iTeos Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are iTeos Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Matthew Gall's compensation dossier · One-time report. No refunds.